Wegovy approved for liver disease: new clinic opportunity

What happened

On 3 July 2026, the Medicines and Healthcare products Regulatory Agency approved semaglutide injection (Wegovy) for the treatment of metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis. MASH is a form of liver disease strongly correlated with obesity and insulin resistance — an estimated 2–5% of the UK population are believed to have the condition, making it a significant expansion of the addressable patient population for semaglutide.

The approval is a conditional marketing authorisation, meaning further confirmatory evidence from an ongoing study is required and the MHRA will review it at least annually. Dosing follows the standard Wegovy escalation schedule from 0.25mg up to 2.4mg weekly, with patients who have a BMI above 30 eligible for an extended dose of up to 7.2mg weekly. NICE has not yet appraised the drug for this indication — an ongoing appraisal (GID-TA11477) will determine NHS availability. For private prescribing, however, the approval is effective immediately.

Who this affects

• Weight-loss clinics and online pharmacies — the MASH approval gives a new clinical indication for semaglutide prescribing. Clinics that already offer Wegovy for weight management can now prescribe for MASH, broadening their service offering without adding new operational complexity.
• GLP-1 prescribers — any clinic or pharmacy prescribing GLP-1 medicines remotely should assess whether their pre-screening and ongoing monitoring protocols cover MASH patients, who typically present with different baseline risks than weight-loss-only patients.
• Private patients with MASH — patients who previously had limited treatment options in the private sector now have a licensed pharmacotherapy, but will need informed prescribing pathways that explain the conditional authorisation status and the lack of long-term outcome data.

What it means

This is the third indication expansion for semaglutide since its launch — moving from diabetes (Ozempic, 2019) to weight management (Wegovy, 2023) to cardiovascular risk reduction (2025) to now MASH. Each expansion normalises the drug class further and extends the addressable market. For private clinics, the practical effect is straightforward: more patients will seek semaglutide prescriptions for conditions beyond weight loss alone. The conditional authorisation does not restrict private prescribing, so clinics can begin treating MASH patients immediately. The main risk is reputational — prescribing for a condition where long-term confirmatory data is still being collected demands clear patient communication and documented informed consent. The GPhC's recent scrutiny of online weight-loss prescribing (covered in our GPhC review analysis) signals that regulators are watching prescribing safeguards across all GLP-1 indications, not just weight management.

What to watch next

The NICE appraisal for semaglutide in MASH (GID-TA11477) is ongoing. An outcome recommending NHS use would significantly increase prescribing volumes, but even without it, the private market is open. Watch for MHRA's first annual review of the conditional authorisation — expected around mid-2027 — and any interim safety signals that could affect the prescribing landscape. Meanwhile, any clinic advertising MASH treatment with semaglutide should be alert to ASA rules on POM advertising: promoting a prescription-only medicine to the public remains prohibited, and the ASA's AI monitoring tools are actively scanning for violations.